Drugs / ISOMIOSAMINE
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04349761 | Jun → Dec 2019 | — | TNF Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06942182 | May 2025 → Mar 2026 overdue | pelvic muscle wasting | TNF Pharmaceuticals, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ISOMIOSAMINE | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068056 ↗ |
| Known as | Isomiosamina | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068056 ↗ |
| Known as | Isomyosamine | “Isomyosamine 5mg capsules” NCT04349761 ↗ |
| Known as | Isomyosmine | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068056 ↗ |
| Modality | Small molecule | — CHEMBL6068056 ↗ |
| Route | Oral | “single oral dose capsules” NCT04349761 ↗ |
| Target | TNF | “reduces inflammation by targeting cytokines like TNF-α and IL-6” NCT06942182 ↗ |